<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04697576</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-20221</org_study_id>
    <secondary_id>NCI-2020-13282</secondary_id>
    <nct_id>NCT04697576</nct_id>
  </id_info>
  <brief_title>Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma</brief_title>
  <official_title>Intralesional Influenza Vaccine for Patients With Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carlo Contreras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial investigates the effects of influenza vaccine in treating patients with&#xD;
      stage I, II, and IV melanoma. While intramuscular administration of influenza vaccine&#xD;
      provides immunization against the influenza virus, giving influenza vaccine directly into the&#xD;
      tumor (intralesional) may decrease the size of the injected melanoma tumor, or the extent of&#xD;
      the melanoma within the body.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the safety and tolerability and determine the maximum tolerated dose of&#xD;
      intralesional (quadrivalent inactivated influenza vaccine (unadjuvanted influenza vaccine)&#xD;
      for patients with a) resectable melanoma as monotherapy, and b) metastatic melanoma,&#xD;
      concurrent with standard of care, single-agent checkpoint inhibition.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate tumor dimensions of injected (Cohorts #1-2) and non-injected lesions (Cohort&#xD;
      #2 only), by caliper measurement. (Clinical endpoint) II. To determine time to disease&#xD;
      progression (local or distant). (Clinical endpoint) III. To evaluate immunohistochemistry&#xD;
      density, cells/mm^2: CD4, CD8, PD-L1, PD1, CD56, CD20, CD45RO, FOXP3. (Tumor-based endpoint)&#xD;
      IV. To evaluate granzyme B H-score. (Tumor-based endpoint) V. To evaluate NanoString Pan&#xD;
      Cancer Immune Profiling Panel. (Tumor-based endpoint) VI. To evaluate tumor-infiltrating&#xD;
      lymphocytes: not identified, present (non-brisk), present (brisk), cannot be determined.&#xD;
      (Tumor-based endpoint) VII. To evaluate degree of tumor regression (percent). (Tumor-based&#xD;
      endpoint) VIII. To evaluate changes in micro ribonucleic acid (microRNA) expression.&#xD;
      (Tumor-based endpoint) IX. To evaluate of flow cytometry for T-cell subset evaluation and&#xD;
      changes in circulating microRNA. (Blood draw endpoint)&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the evidence of immunologic activation in blood and tissue specimens.&#xD;
&#xD;
      OUTLINE: This is dose-escalation study. Patients are assigned to 1 of 2 cohorts.&#xD;
&#xD;
      COHORT I: Patients receive quadrivalent inactivated influenza vaccine intramuscularly (IM) on&#xD;
      day 0 and intratumorally on days 2 and 14 in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients then undergo surgery on day 28.&#xD;
&#xD;
      COHORT II: Patients receive quadrivalent inactivated influenza vaccine IM on day 0 and&#xD;
      intratumorally on days 2, 14, 28, 42, 56, 70, 84, and 98 in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients also receive standard of care ipilimumab,&#xD;
      nivolumab, or pembrolizumab.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to 1 year after the last intra-tumoral dose</time_frame>
    <description>Frequency and severity of AEs and tolerability of the regimen will be collected and summarized by descriptive statistics. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. All patients who have received at least one dose of the therapeutic agents will be evaluable for toxicity and tolerability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) in Cohorts #1 and #2</measure>
    <time_frame>Up to 98 days</time_frame>
    <description>Will employ the Bayesian optimal interval design to find the MTD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor dimensions of injected (Cohorts #1)</measure>
    <time_frame>Up to 1 year after the last intra-tumoral dose</time_frame>
    <description>Will be assessed by caliper measurement. Tumor dimensions will be summarized using descriptive statistics (i.e. mean with standard deviations, or median with range).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor dimensions of non-injected lesions (Cohort #2)</measure>
    <time_frame>Up to 1 year after the last intra-tumoral dose</time_frame>
    <description>Will be assessed by caliper measurement. Tumor dimensions will be summarized using descriptive statistics (i.e. mean with standard deviations, or median with range).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression (local or distant)</measure>
    <time_frame>From the start of treatment until the documentation of local or distant disease progression, assessed up to 1 year</time_frame>
    <description>Time to disease progression will be analyzed using Kaplan-Meier method, resulting in median survival times with 95% confidence interval, assuming sufficient events have occurred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis</measure>
    <time_frame>Up to 1 year after the last intra-tumoral dose</time_frame>
    <description>Will analyze immunohistochemistry density, cells/mm^2 of CD4, CD8, PD-L1, PD1, CD56, CD20, CD45RO, FOXP3. Summary statistics will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Granzyme B H-score</measure>
    <time_frame>Up to 1 year after the last intra-tumoral dose</time_frame>
    <description>Summary statistics will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NanoString Pan Cancer Immune Profiling Panel</measure>
    <time_frame>Up to 1 year after the last intra-tumoral dose</time_frame>
    <description>Summary statistics will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor-infiltrating lymphocytes analysis</measure>
    <time_frame>Up to 1 year after the last intra-tumoral dose</time_frame>
    <description>Will analyze tumor-infiltrating lymphocytes: not identified, present (non-brisk), present (brisk), cannot be determined. Summary statistics will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of tumor regression (percent)</measure>
    <time_frame>Up to 1 year after the last intra-tumoral dose</time_frame>
    <description>Summary statistics will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in micro ribonucleic acid (RNA) expression</measure>
    <time_frame>Baseline up to 1 year after the last intra-tumoral dose</time_frame>
    <description>Summary statistics will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell subset evaluation and changes in circulating microRNA</measure>
    <time_frame>Up to 1 year after the last intra-tumoral dose</time_frame>
    <description>Summary statistics will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Clinical Stage I Cutaneous Melanoma AJCC v8</condition>
  <condition>Clinical Stage IA Cutaneous Melanoma AJCC v8</condition>
  <condition>Clinical Stage IB Cutaneous Melanoma AJCC v8</condition>
  <condition>Clinical Stage II Cutaneous Melanoma AJCC v8</condition>
  <condition>Clinical Stage IIA Cutaneous Melanoma AJCC v8</condition>
  <condition>Clinical Stage IIB Cutaneous Melanoma AJCC v8</condition>
  <condition>Clinical Stage IIC Cutaneous Melanoma AJCC v8</condition>
  <condition>Clinical Stage IV Cutaneous Melanoma AJCC v8</condition>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Cohort I (quadrivalent inactivated influenza vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive influenza vaccine IM on day 0 and intratumorally on days 2 and 14 in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort II (quadrivalent inactivated influenza vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive influenza vaccine IM on day 0 and intratumorally on days 2, 14, 28, 42, 56, 70, 84, and 98 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care ipilimumab, nivolumab, or pembrolizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>immune checkpoint inhibitor</description>
    <arm_group_label>Cohort II (quadrivalent inactivated influenza vaccine)</arm_group_label>
    <other_name>Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody</other_name>
    <other_name>BMS-734016</other_name>
    <other_name>MDX-010</other_name>
    <other_name>MDX-CTLA4</other_name>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>immune checkpoint inhibitor</description>
    <arm_group_label>Cohort II (quadrivalent inactivated influenza vaccine)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>MDX-1106</other_name>
    <other_name>NIVO</other_name>
    <other_name>ONO-4538</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>immune checkpoint inhibitor</description>
    <arm_group_label>Cohort II (quadrivalent inactivated influenza vaccine)</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Inactivated Influenza Vaccine</intervention_name>
    <description>Given IM and intratumorally</description>
    <arm_group_label>Cohort I (quadrivalent inactivated influenza vaccine)</arm_group_label>
    <arm_group_label>Cohort II (quadrivalent inactivated influenza vaccine)</arm_group_label>
    <other_name>Fluzone Quadrivalent</other_name>
    <other_name>Fluzone Quadrivalent Influenza Vaccine</other_name>
    <other_name>QIV</other_name>
    <other_name>Quadrivalent Influenza Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Resection</intervention_name>
    <description>Undergo surgical resection</description>
    <arm_group_label>Cohort I (quadrivalent inactivated influenza vaccine)</arm_group_label>
    <other_name>Surgical Resection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 90 years of age&#xD;
&#xD;
          -  Histologically confirmed cutaneous melanoma, clinical stage I/II (Cohort #1), or stage&#xD;
             IV (Cohort #2) cutaneous melanoma&#xD;
&#xD;
          -  At least one, biopsy-proven, palpable melanoma tumor deposit suitable for&#xD;
             intralesional injection measuring &gt;= 1 cm&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy or intolerance to influenza vaccination&#xD;
&#xD;
          -  Subjects with condition requiring systemic treatment with either corticosteroids (&gt; 10&#xD;
             mg daily prednisone/equivalent) or other immunosuppressive medications within 14 days&#xD;
             of study drug administration&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease&#xD;
&#xD;
          -  Active brain metastasis or leptomeningeal metastasis&#xD;
&#xD;
          -  Diagnostic biopsy of ocular or mucosal melanoma&#xD;
&#xD;
          -  Any melanoma therapy within 6 months of enrollment; though prior surgical resection is&#xD;
             permitted&#xD;
&#xD;
          -  Incarcerated patients&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) positive patients&#xD;
&#xD;
          -  Pregnant or lactating patients&#xD;
&#xD;
          -  Patients incapable of independently providing consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo M Contreras, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>The Ohio State University Comprehensive Cancer Center</last_name>
    <phone>800-293-5066</phone>
    <email>OSUCCCClinicaltrials@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo M. Contreras, MD</last_name>
      <phone>614-366-3681</phone>
      <email>Carlo.Contreras@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Carlo M. Contreras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Carlo Contreras</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

